Resultats de la cerca - Chang, Ching-Fu

PD-L1 Immunohistochemistry Comparability and Their Correlation with Clinical Characteristics in NSCLC per Wu, Chiao-En, Chang, Ching-Fu, Kou-Sheng, Liao, Chiang, Ju, Lee, Shih-Wei, Chiu, Yu-Chi

Obtenir text complet Obtenir text complet Obtenir text complet

Feasibility and effectiveness of afatinib for poor performance status patients with EGFR-mutation-positive non-small-cell lung cancer: a retrospective cohort study per Wu, Chiao-En, Chang, Ching-Fu, Huang, Chen-Yang, Yang, Cheng-Ta, Kuo, Chih-Hsi Scott, Hsu, Ping-Chih, Chang, John Wen-Cheng

Obtenir text complet Obtenir text complet Obtenir text complet

Comparison of Different Tyrosine Kinase Inhibitors for Treatment of Poor Performance Status Patients with EGFR-Mutated Lung Adenocarcinoma per Wu, Chiao-En, Chang, Ching-Fu, Huang, Chen-Yang, Yang, Cheng-Ta, Kuo, Chih-Hsi Scott, Hsu, Ping-Chih, Chang, John Wen-Cheng

Obtenir text complet Obtenir text complet Obtenir text complet

Prognostic Factors for Advanced Pancreatic Cancer Treated with Gemcitabine Plus S-1: Retrospective Analysis and Development of a Prognostic Model per Chang, Ching-Fu, Huang, Pei-Wei, Chen, Jen-Shi, Chen, Yen-Yang, Lu, Chang-Hsien, Chang, Pei-Hung, Hung, Yu-Shin, Chou, Wen-Chi

Obtenir text complet Obtenir text complet Obtenir text complet

Risk Stratification Using a Novel Nomogram for 2190 EGFR-Mutant NSCLC Patients Receiving the First or Second Generation EGFR-TKI per Chang, John Wen-Cheng, Huang, Chen-Yang, Fang, Yueh-Fu, Chang, Ching-Fu, Yang, Cheng-Ta, Kuo, Chih-Hsi Scott, Hsu, Ping-Chih, Wu, Chiao-En

Obtenir text complet Obtenir text complet Obtenir text complet

Epidermal growth factor receptor tyrosine kinase inhibitors for de novo T790M mutation: A retrospective study of 44 patients per Chang, John Wen‐Cheng, Huang, Chen‐Yang, Fang, Yueh‐Fu, Chang, Ching‐Fu, Yang, Cheng‐Ta, Kuo, Chih‐Hsi Scott, Hsu, Ping‐Chih, Wu, Chiao‐En

Obtenir text complet Obtenir text complet Obtenir text complet

Prognostic Value of Lymph Node-To-Primary Tumor Standardized Uptake Value Ratio in Esophageal Squamous Cell Carcinoma Treated with Definitive Chemoradiotherapy per Lin, Chia-Hsin, Hung, Tsung-Min, Chang, Yu-Chuan, Hsieh, Chia-Hsun, Shih, Ming-Chieh, Huang, Shih-Ming, Yang, Chan-Keng, Chang, Ching-Fu, Chan, Sheng-Chieh, Yap, Wing-Keen

Obtenir text complet Obtenir text complet Obtenir text complet

Validation and application of a prognostic model for patients with advanced pancreatic cancer receiving palliative chemotherapy per Huang, Pei‐Wei, Chang, Ching‐Fu, Hung, Chia‐Yen, Hsueh, Shun‐Wen, Chang, Pei‐Hung, Yeh, Kun‐Yun, Chen, Jen‐Shi, Chen, Yen‐Yang, Lu, Chang‐Hsien, Hung, Yu‐Shin, Chou, Wen‐Chi

Obtenir text complet Obtenir text complet Obtenir text complet

The association between immune-related adverse events and survival outcomes in Asian patients with advanced melanoma receiving anti-PD-1 antibodies per Wu, Chiao-En, Yang, Chan-Keng, Peng, Meng-Ting, Huang, Pei-Wei, Chang, Ching-Fu, Yeh, Kun-Yun, Chen, Chun-Bing, Wang, Chih-Liang, Hsu, Chao-Wei, Chen, I-Wen, Lin, Cheng-Tao, Ueng, Shir-Hwa, Lin, Gigin, Lin, Yu-Fen, Cheng, Chi-Yuan, Chang, John Wen-Cheng

Obtenir text complet Obtenir text complet Obtenir text complet